Publications by authors named "Angelique Brzustowski"
Background & Aims: Despite its high prevalence in the western world metabolic dysfunction-associated steatotic liver disease (MASLD) does not benefit from targeted pharmacological therapy. We measured healthcare utilisation and identified factors associated with high-cost MASLD patients in France.
Methods: The prevalent population with MASLD (including non-alcoholic steatohepatitis) in the CONSTANCES cohort, a nationally representative sample of 200,000 adults aged between 18 and 69, was linked to the French centralised national claims database (SNDS).
Article Synopsis
- - This study investigates the potential of a new NRF2 activator, S217879, to treat metabolic-associated fatty liver disease (MAFLD) and fibrosis using a 3D model of patient-derived liver slices.
- - After treating liver slices from MAFLD patients with S217879, researchers found no toxic effects and observed significant improvements in liver health, including reduced triglycerides, inflammation, and DNA damage compared to untreated samples.
- - The results highlight that both S217879 and elafibranor, a standard treatment, effectively activate certain genes related to liver metabolism and antioxidant responses, with S217879 showing additional benefits in lowering inflammatory markers.
Background: No prospective diagnostic studies have directly compared widespread non-invasive liver tests in patients with type 2 diabetes (T2D) using the intention-to-diagnose method for each of the three main histological features of metabolic dysfunction associated steatotic liver disease - namely fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), and steatosis.
Aims: To compare the performance of nine tests using the intention-to-diagnose rather than the standard method, which would exclude non-evaluable participants METHODS: Biopsy was used as the reference with predetermined cut-offs, advanced fibrosis being the main endpoint. The Nash-FibroTest panel including FibroTest-T2D, SteatoTest-T2D and MashTest-T2D was optimised for type 2 diabetes.
Background: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, which is associated with features of metabolic syndrome. NAFLD may progress in a subset of patients into nonalcoholic steatohepatitis (NASH) with liver injury resulting ultimately in cirrhosis and potentially hepatocellular carcinoma. Today, there is no approved treatment for NASH due to, at least in part, the lack of preclinical models recapitulating features of human disease.
View Article and Find Full Text PDFArticle Synopsis
- In patients with non-alcoholic fatty liver disease (NAFLD), alpha-2 macroglobulin (A2M), apolipoprotein A1 (ApoA1), and haptoglobin levels are linked to liver fibrosis and inflammation, with specific trends observed in those with type 2 diabetes mellitus (T2DM).
- The study analyzed data from three different cohorts to examine the effects of T2DM on these protein levels related to liver health before and during the COVID-19 pandemic.
- Results showed that patients with NAFLD and T2DM showed greater increases in A2M and haptoglobin, along with a significant decrease in ApoA1, especially during the pandemic, indicating a heightened impact of T
Article Synopsis
- A recent study focused on predicting non-alcoholic liver disease in patients with type 2 diabetes using non-invasive blood tests for fibrosis, NASH, and steatosis.
- The investigation involved 272 patients and assessed the performance of a new testing panel called Nash-FibroTest, which uses an Obuchowski measure for accuracy rather than traditional methods.
- Results showed that the panel effectively diagnosed stages of fibrosis and grades of NASH and steatosis from a single blood sample, outperforming traditional assessment methods in some aspects.